Business

Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

BURNABY, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today

articleXenon Pharmaceuticals Inc.June 1, 20225/company/xenon-pharmaceuticals-inc/news/xenon-pharmaceuticals-to-present-at-the-2022-jefferies-healthcare-conference-2022-06
Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

About this update from Xenon Pharmaceuticals Inc.

[{"type":"text","content":"BURNABY, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conference to be held June 8-10, 2022 in New York, NY. Company Presentation Details: Date:Time:Presenter:Wednesday, June 8, 20222:30 pm Eastern TimeIan Mortimer, President and CEO A webcast of the company presentation will also be broadcast live on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com. “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Investor/Media Contact:Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604.484.3353Email: [email protected] \nSource: Xenon Pharmaceuticals Inc.","length":4177,"tagName":"div"}]

More updates from Xenon Pharmaceuticals Inc.